Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Disturbances in the reward processes in schizophrenia and its relation to dopamine activity: A longitudinal study in antipsychotic-naive first-episode schizophrenic patients

Projekt: Typer af projekter

Vis graf over relationer
In this Ph.D. study we plan to examine how the expected changes in reward processing explored by use of fMRI in the collaborating Ph.D. study by Mette Ødegaard Nielsen are related to striatal dopamine D2/3 binding potentials (BP) and psychopathology in antipsychotic-naïve first-episode schizophrenia patients - and, not the least, how these disturbances are modulated by interventions with a D2/3 blocker (amisulpride). We expect that blockade of striatal D2/3 receptors to a certain degree will correlate positively with improvement in positive
psychotic symptoms and decrease in salience abnormality (as measured with fMRI) whereas blockade will correlate negatively with valence processing and negative symptoms. We further expect to find an individual narrow window of D2/3 blockade within which there is a positive effect on salience disturbances and positive symptoms without a negative effect on valence disturbances and negative symptoms.The study design is the same as for the previous Ph.D. study, i.e. a 6 week case-control follow-up study of 30 antipsychotic-naïve patients with schizophrenia and 30 matched controls. Since inclusion to this part of the study was delayed compared to the collaborating Ph.D. study, inclusion will continue after Mette Ødegaard Nielsen has finished her part of the study. After baseline examinations the patients receive an antipsychotic drug with a selective affinity for D2/D3 receptors. As first generation antipsychotics are not recommended for first episode patients, amisulpride has been chosen for the project. To examine the dopamine activity and density of D2 receptors we use SPECT (Single Photon Emissions Computerised Tomography) with a D2/D3 ligand 123Iodbenzamid (123IBZM). For ethical reasons the healthy controls are not re-scanned at the 6 week follow-up.The SPECT scans are performed at the Unit of Functional Imaging, Glostrup University Hospital. The plasma parent compound is determined with HPLC, which is performed at NRU/Cimbi.
StatusAfsluttet
Periode01/09/201131/08/2014
FinansieringskildeAnden offentlig støtte (Offentlig)
ForskningsprogramSamfin. PHD skolen/ Psykiatrisk Center Glostrup
Beløb750,00 Danske Kroner
Årstal2010

ID: 32195142